Background: INNO-LiPA HBV Genotyping (LiPA HBV GT) and INNO-LiPA HBV PreCore (LiPA HBV PC) are commercially available assays for hepatitis B virus (HBV) characterization. These assays are labor-intensive and may be prone to exogenous DNA contamination due to their use of nested PCR amplification procedures and lack of contamination control measures.
Objective: Standardized, single-round INNO-LiPA PCR amplification protocols incorporating uracil N-glycosylase and automated sample processing by the MagNA Pure LC instrument were evaluated.
Study Design: HBV standards containing 10,000, 1000, 100, 10, and 0 IU/mL were analyzed to determine the analytical sensitivity and reproducibility of these modified procedures. One hundred clinical serum specimens with viral titers ranging from 390 to 16,900,000 IU/mL were tested by modified LiPA HBV GT, while 34 specimens with viral titers ranging from 378 to 11,600,000 IU/mL were tested by modified LiPA HBV PC.
Results: Modified LiPA HBV GT and LiPA HBV PC each yielded analytical sensitivities of 100% at an HBV DNA level of 1000 IU/mL and 90% at a level of 100 IU/mL. Among clinical specimens, success rates for both INNO-LiPA procedures were > or =94%.
Conclusions: Both modified INNO-LiPA procedures were sensitive and reproducible, with improved efficiency and suitability for routine laboratory use.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jcv.2006.08.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of a next generation sequencing assay for Hepatitis B antiviral drug resistance on the oxford nanopore system.
J Clin Virol
January 2025
Division of Medical Microbiology and Virology, St. Paul's Hospital, Providence Health Care, Vancouver, British Columbia, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:
Background: Next-generation sequencing (NGS) for Hepatitis B virus (HBV) antiviral resistance (AVR) testing is a highly sensitive diagnostic method, able to detect low-level mutant subpopulations. Our clinical virology laboratory previously transitioned from DNA hybridization (INNO-LiPA) to NGS, initially with the GS Junior System and subsequently the MiSeq. The Oxford Nanopore Technology (ONT) sequencing system was evaluated for HBV resistance testing, with regards to sequencing accuracy and turn-around time.
View Article and Find Full Text PDFHepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients.
Medicina (Kaunas)
April 2022
Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Article Synopsis
- Romania has a high prevalence of hepatitis B virus (HBV) in HIV patients, primarily affecting those parenterally infected in childhood; this study aimed to examine the genotypes and antiviral resistance in these co-infected individuals.
- Among 117 patients studied, 73.5% had detectable HBV-DNA, with genotype A prevalent in long-term treatment patients and genotype D found mostly in recent injecting drug users; both genotypes showed resistance mutations.
- The findings highlight significant differences in liver disease progression and treatment resistance between the two genotypes, underscoring the need for monitoring and targeted treatment strategies for co-infected patients.
DISTRIBUTION OF HBV GENOTYPES AMONG GEORGIAN PATIENTS OF DIFFERENT AGE GROUPS.
Georgian Med News
January 2022
1Gastroenterology & Hepatology department, Medical center Mrcheveli, Tbilisi, Georgia.
Hepatitis B virus (HBV) infection is one of the major healthcare problems in Georgia with a prevalence of 2.9% in the adult population. There is no published data on HBV genotype distribution among different age groups in the country.
View Article and Find Full Text PDFBackground: Blood donor selection, along with laboratory screening of the HBV, plays a pivotal role in providing safe blood products. This study was aimed to evaluate the prevalence, genotype, and drug resistance prediction of HBV among Iranian blood donors.
Methods: This cross-sectional study was conducted on 47,506 blood donors referring to Golestan Blood Center from March 21, 2018, to March 20, 2019.
Developing a sensitive HBV genotyping assay for HBV DNA suppressed patients using both DNA and RNA sequencing.
J Med Virol
December 2020
Gilead Sciences, Inc., Foster City, California.
Hepatitis B virus (HBV) genotypes impact treatment outcomes and disease progression. The current genotyping methods have limitations in patients with low HBV viral load. In this study, a more sensitive assay has been developed for determining the HBV genotype in HBV DNA suppressed patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!